Impact of GH administration on skeletal endpoints in adults with overweight/obesity.

ABSTRACT:

Objective

Overweight/obesity is associated with relative growth hormone (GH) deficiency and increased fracture risk. We hypothesized that GH administration would improve bone endpoints in individuals with overweight/obesity.

Design

An 18-month, randomized, double-blind, placebo-controlled study of GH, followed by 6-month observation.

Methods

In this study, 77 adults (53% men), aged 18-65 years, BMI ≥ 25 kg/m2, and BMD T- or Z-score ≤ -1.0 were randomized to daily subcutaneous GH or placebo, targeting IGF1 in the upper quartile of the age-appropriate normal range. Forty-nine completed 18 months. DXA, volumetric quantitative CT, and high-resolution peripheral quantitative CT were performed.

Results

Pre-treatment mean age (48 ± 12 years), BMI (33.1 ± 5.7 kg/m2), a

SUBMITTER: Dichtel LE 

PROVIDER: S-EPMC9400128 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature